62 related articles for article (PubMed ID: 38627334)
21. Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.
Dubinski D; Hattingen E; Senft C; Seifert V; Peters KG; Reiss Y; Devraj K; Plate KH
J Cereb Blood Flow Metab; 2019 Aug; 39(8):1460-1468. PubMed ID: 31238763
[TBL] [Abstract][Full Text] [Related]
22. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Sabel M; Hau P; Kortmann RD; Krex D; Grauer O; Goldbrunner R; Schnell O; Bähr O; Uhl M; Seidel C; Tabatabai G; Kowalski T; Ringel F; Schmidt-Graf F; Suchorska B; Brehmer S; Weyerbrock A; Renovanz M; Bullinger L; Galldiks N; Vajkoczy P; Misch M; Vatter H; Stuplich M; Schäfer N; Kebir S; Weller J; Schaub C; Stummer W; Tonn JC; Simon M; Keil VC; Nelles M; Urbach H; Coenen M; Wick W; Weller M; Fimmers R; Schmid M; Hattingen E; Pietsch T; Coch C; Glas M;
Lancet; 2019 Feb; 393(10172):678-688. PubMed ID: 30782343
[TBL] [Abstract][Full Text] [Related]
23. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline.
Paw Cho Sing E; Robinson PD; Flank J; Holdsworth M; Thackray J; Freedman J; Gibson P; Orsey AD; Patel P; Phillips R; Portwine C; Raybin JL; Cabral S; Sung L; Dupuis LL
Pediatr Blood Cancer; 2019 May; 66(5):e27646. PubMed ID: 30729654
[TBL] [Abstract][Full Text] [Related]
24. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Somerfield MR; Lyman GH
J Clin Oncol; 2017 Oct; 35(28):3240-3261. PubMed ID: 28759346
[TBL] [Abstract][Full Text] [Related]
25. The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study.
Flank J; Sparavalo J; Vol H; Hagen L; Stuhler R; Chong D; Courtney S; Doyle JJ; Gassas A; Schechter T; Dupuis LL
Bone Marrow Transplant; 2017 Sep; 52(9):1294-1299. PubMed ID: 28581463
[TBL] [Abstract][Full Text] [Related]
26. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
Roila F; Molassiotis A; Herrstedt J; Aapro M; Gralla RJ; Bruera E; Clark-Snow RA; Dupuis LL; Einhorn LH; Feyer P; Hesketh PJ; Jordan K; Olver I; Rapoport BL; Roscoe J; Ruhlmann CH; Walsh D; Warr D; van der Wetering M;
Ann Oncol; 2016 Sep; 27(suppl 5):v119-v133. PubMed ID: 27664248
[No Abstract] [Full Text] [Related]
27. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Jakacki RI; Cohen KJ; Buxton A; Krailo MD; Burger PC; Rosenblum MK; Brat DJ; Hamilton RL; Eckel SP; Zhou T; Lavey RS; Pollack IF
Neuro Oncol; 2016 Oct; 18(10):1442-50. PubMed ID: 27006176
[TBL] [Abstract][Full Text] [Related]
28. Corticosteroid use in neuro-oncology: an update.
Roth P; Happold C; Weller M
Neurooncol Pract; 2015 Mar; 2(1):6-12. PubMed ID: 26034636
[TBL] [Abstract][Full Text] [Related]
29. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
[TBL] [Abstract][Full Text] [Related]
30. Glucocorticoids and endothelial cell barrier function.
Salvador E; Shityakov S; Förster C
Cell Tissue Res; 2014 Mar; 355(3):597-605. PubMed ID: 24352805
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Jakacki RI; Yates A; Blaney SM; Zhou T; Timmerman R; Ingle AM; Flom L; Prados MD; Adamson PC; Pollack IF
Neuro Oncol; 2008 Aug; 10(4):569-76. PubMed ID: 18497327
[TBL] [Abstract][Full Text] [Related]
32. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
33. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials.
Neymark N; Crott R
Support Care Cancer; 2005 Oct; 13(10):812-8. PubMed ID: 15834590
[TBL] [Abstract][Full Text] [Related]
34. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
35. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.
Ballatori E; Roila F
Health Qual Life Outcomes; 2003 Sep; 1():46. PubMed ID: 14521717
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine-a case series.
Schellekens KPJ; Hageman SB; Haverkate EC; van de Wetering MD; Engels FK; Brinksma A; de Vos-Kerkhof E
Support Care Cancer; 2024 Apr; 32(5):290. PubMed ID: 38627334
[TBL] [Abstract][Full Text] [Related]
37. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
39. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
40. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
